Prednicarbate
Clinical data | |
---|---|
Other names | [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a604021 |
Routes of administration | Topical |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.070.516 |
Chemical and physical data | |
Formula | C27H36O8 |
Molar mass | 488.57 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Prednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. Compared to other topical corticosteroids, like betamethasone, repeated prednicarbate use does not cause skin atrophy as quickly.[citation needed] Corticosteroids have always been an important part of the pharmacological arsenal of dermatology; however, their tendency to produce side-effects has caused the need to search for new preparations.
It is nonhalogenated.[1]
References
- ^ Gupta AK, Chow M (2004). "A review of prednicarbate (Dermatop)". Skin Therapy Lett. 9 (10): 5–6, 9. PMID 15657633.